Clinicals.

Download the eBook

keraGEN-iV® measurably reduces hair fall by 43.1%.

Prior work on keraGEN-IV® identified using in vitro studies on human keratinocytes showed that increased collagen IV expression is induced by this keratin protein. The keraGEN-IV® action of inducing collagen IV expression translates to measurable improvement in hair anchoring, specifically a 43.1% reduction in hair loss in women aged 45-60 with stressed or damaged hair.

Volunteers taking the keraGEN-IV® supplement demonstrated a substantial and statistically significant reduction in hair pull scores on day 60. Reduction compared to day 0 was -43.1% (p≤0.005). The gentle pulling action triggering hair loss is typical of that experienced during combing or styling when hair is damaged through chemical treatments, colour, styling or during peri- or post-menopause.

Clinical Research into keraGEN-IV® was conducted by Laboratoire BIO-EC to determine the effects of a nutritional supplement on hair and skin health.
keraGEN-iV® measurably improves skin structure.

  • Increases skin elasticity by 10.1%
  • Reduces skin moisture loss by 12.5%

Increases skin elasticity by 10.1%

Skin elasticity measurements on day 30 for volunteers taking the keraGEN-IV® were substantially higher on day 60 at 10.1% (p≤0.005) compared to day 0. keraGEN-IV® compared to placebo showed a statistically significant improvement on day 60 (p≤0.05).

Reduces skin moisture loss by 12.5%

Skin barrier function is an important indicator of skin health. The trans epidermal water loss (TEWL) assessment evaluates the skin barrier function efficacy and is indicative of the skin structure and integrity of the to the stratum corneum. The TEWL value is inversely proportional to the barrier function. TEWL measurements on day 30 volunteers taking the keraGEN-IV® supplement were lower at -12.5% less compared to day 0 (p≤0.05). The measured 12.5% reduction in TEWL may arise from the in improvement of skin structure due to collagen IV expression induced by keraGEN-IV®.

keraGEN-IV® study demonstrating hair & skin improvements

keraGEN-IV® affects metabolic pathways associated with hair, skin and nail health. A strong body of scientific data supports each component of the mechanisms of action.

  • Randomised, double-blind, placebo controlled study conducted by independent test lab BIO-EC under the French Public Health Code.
  • Volunteers identified as having damaged or stressed hair and healthy skin according to a dermatologist assessment were selected.
Method
*Dermatological assessment of volunteers’ hair and skin

* Small area of scalp shaved for hair growth analysis and initial measurements made of hair and skin

* Trial products were administered and consumed once a day for the 60 day study duration

*Placebo control: Microcrystalline cellulose, 750mg. Two capsules taken daily.

*Study Product: KeraGEN IV 200mg, Microcrystalline cellulose 550mg. Two capsules taken daily
Tested on day 0, day 30 and day 60.
Hair loss through hair pulling – indicative of follicle and scalp health

Trans epidermal water loss – indicative of skin structure and integrity

Cutometry – assesses the state of skin firmness/elasticity.